B. Dahlbäck, Pro-and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders, Int. J. Lab. Hematol, vol.38, issue.1, pp.4-11, 2016.

K. Segers, B. Dahlbäck, and G. A. Nicolaes, Coagulation factor V and thrombophilia: background and mechanisms, Thromb. Haemost, vol.98, pp.530-542, 2007.

L. Shen and B. Dahlbäck, Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa, J. Biol. Chem, vol.269, pp.18735-18738, 1994.

S. Peraramelli, Role of exosite binding modulators in the inhibition of Fxa by TFPI, Thromb. Haemost, vol.115, pp.580-590, 2016.

S. Santamaria, Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation, J. Biol. Chem, vol.292, pp.9335-9344, 2017.

H. L. Vos, Inherited defects of coagulation Factor V: the thrombotic side, J. Thromb. Haemost. JTH, vol.4, pp.35-40, 2006.

R. M. Bertina, Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature, vol.369, pp.64-67, 1994.

N. L. Smith, Association of genetic variations with nonfatal venous thrombosis in postmenopausal women, JAMA, vol.297, pp.489-498, 2007.

P. E. Morange and D. A. Tregouet, Lessons from genome-wide association studies in venous thrombosis, J. Thromb. Haemost. JTH, vol.9, issue.1, pp.258-264, 2011.

I. D. Bezemer, L. A. Bare, A. R. Arellano, P. H. Reitsma, and F. R. Rosendaal, Updated analysis of gene variants associated with deep vein thrombosis, JAMA, vol.303, pp.421-422, 2010.

A. E. Dahm, Candidate gene polymorphisms and the risk for pregnancy-related venous thrombosis, Br. J. Haematol, vol.157, pp.753-761, 2012.

N. L. Smith, Replication of findings on the association of genetic variation in 24 hemostasis genes and risk of incident venous thrombosis, J. Thromb. Haemost. JTH, vol.7, pp.1743-1746, 2009.

M. Germain, Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism, Am. J. Hum. Genet, vol.96, pp.532-542, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01259946

O. V. Gran, Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism, Haematologica, vol.101, pp.1046-1053, 2016.

H. Kostka, Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients, Thromb. Res, vol.99, pp.539-547, 2000.

F. Mingozzi, A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers, Thromb. Haemost, vol.89, pp.983-989, 2003.

E. Pearce, Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction, Circ. Res, vol.97, pp.1070-1076, 2005.

D. A. Tregouet, Specific haplotypes of the P-selectin gene are associated with myocardial infarction, Hum. Mol. Genet, vol.11, pp.2015-2023, 2002.

A. H. Klerkx, Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-> A polymorphism and a novel promoter variant are independently associated with CETP concentration, Hum. Mol. Genet, vol.12, pp.1111-1123, 2003.

F. Soubrier, High-resolution genetic mapping of the ACE-linked QTL influencing circulating ACE activity, Eur. J. Hum. Genet, vol.10, pp.553-561, 2002.

E. Thorelli, R. J. Kaufman, and B. Dahlbäck, The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V, J. Biol. Chem, vol.273, pp.16140-16145, 1998.

J. P. Wood, Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation, Proc. Natl. Acad. Sci. USA, vol.110, pp.17838-17843, 2013.

L. M. Vincent, Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPI?, J. Clin. Invest, vol.123, pp.3777-3787, 2013.

P. Van-doorn, J. Rosing, S. J. Wielders, T. M. Hackeng, and E. Castoldi, The C-terminus of tissue factor pathway inhibitor-? inhibits factor V activation by protecting the Arg1545 cleavage site, J. Thromb. Haemost. JTH, vol.15, pp.140-149, 2017.

M. C. De-visser, Determinants of the APTT-and ETP-based APC sensitivity tests, J. Thromb. Haemost. JTH, vol.3, pp.1488-1494, 2005.

P. Suchon, Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk, Sci. Rep, vol.7, p.45507, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01517355

M. Germain, Caution in interpreting results from imputation analysis when linkage disequilibrium extends over a large distance: a case study on venous thrombosis, PloS One, vol.7, p.38538, 2012.

A. Robert, V. Eschwège, H. Hameg, L. Drouet, and M. F. Aillaud, Anticoagulant response to Agkistrodon contortrix venom (ACV test): a new global test to screen for defects in the anticoagulant protein C pathway, Thromb. Haemost, vol.75, pp.562-566, 1996.

T. Oudot-mellakh, Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project, Br. J. Haematol, vol.157, pp.230-239, 2012.

H. C. Hemker, The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability, Pathophysiol. Haemost. Thromb, vol.32, pp.249-253, 2002.

J. M. Brugge, Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation, J. Thromb. Haemost. JTH, vol.3, pp.2695-2702, 2005.

D. A. Tregouet and V. Garelle, A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies, Bioinformatics, vol.23, pp.1038-1039, 2007.

E. A. Thompson, The detection of linkage disequilibrium between closely linked markers: RFLPs at the AI-CIII apolipoprotein genes, Am. J. Hum. Genet, vol.42, pp.113-124, 1988.